Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 2
1949 1
1950 1
1951 2
1952 2
1953 3
1954 2
1956 1
1957 1
1958 5
1959 3
1960 3
1961 1
1962 4
1963 7
1964 2
1965 4
1966 9
1967 10
1968 11
1969 11
1970 13
1971 11
1972 11
1973 17
1974 28
1975 16
1976 24
1977 15
1978 14
1979 15
1980 32
1981 25
1982 17
1983 16
1984 23
1985 28
1986 30
1987 30
1988 34
1989 42
1990 47
1991 36
1992 42
1993 45
1994 34
1995 40
1996 55
1997 41
1998 45
1999 46
2000 58
2001 48
2002 49
2003 57
2004 41
2005 58
2006 56
2007 51
2008 60
2009 66
2010 48
2011 62
2012 70
2013 83
2014 73
2015 69
2016 80
2017 83
2018 77
2019 76
2020 13
Text availability
Article attribute
Article type
Publication date

Search Results

2,122 results
Results by year
Filters applied: . Clear all
Page 1
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng J, et al. Cancer Discov 2018. Among authors: Roberts PJ. PMID 29101163 Free PMC article.
. ©2017 AACR.See related commentary by Balko and Sosman, p. 143See related article by Jenkins et al., p. 196This article is highlighted in the In This Issue feature, p. 127....
. ©2017 AACR.See related commentary by Balko and Sosman, p. 143See related article by Jenkins et al., p. 196This article is hi …
A Leadless Intracardiac Transcatheter Pacing System
Reynolds D, et al. N Engl J Med 2016 - Clinical Trial. Among authors: Roberts PR. PMID 26551877 Free article.
The rate of the primary efficacy end point was 98.3% (95% CI, 96.1 to 99.5; P<0.001 for the comparison with the efficacy performance goal of 80%) among 292 of 297 patients with paired 6-month data. Although there were 28 major complications in 25 patients, patients with transcatheter pacemakers had significantly fewer major complications than did the control patients (hazard ratio, 0.49; 95% CI, 0.33 to 0.75; P=0.001). ...
The rate of the primary efficacy end point was 98.3% (95% CI, 96.1 to 99.5; P<0.001 for the comparison with the efficacy performan …
2,122 results
Jump to page
Feedback